-
Mashup Score: 0
The development of zandelisib for the treatment of B-cell malignancies has been discontinued outside of Japan.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The development of zandelisib for the treatment of B-cell malignancies has been discontinued outside of Japan.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Zandelisib 60 mg once daily on an intermittent dosing schedule was safe, with low frequency of grade 3 or worse adverse events, warranting the ongoing global phase 2 and phase 3 trials.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Findings from a phase 1 study concluded zandelisib given to patients with relapsed/refractory B-cell malignancies at 60 mg once daily in an intermittent dosing schedule reflected in a positive safety profile.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
ICYMI: The development of #zandelisib for the treatment of B-cell malignancies has been discontinued outside of Japan. #hematology #oncology https://t.co/Ru9vP1cccr https://t.co/11zQlCqaVZ